On August 15 2011, Facebook got rid of its exception for the pharmaceutical industry regarding ‘white-listing’, allowing commentary onto industry-sponsored Facebook pages. The result – the industry must interact or withdraw from the platform completely. This article examines how pharma should respond to these changes.

View full article